Long-term stability of alpha-1-antichymotrypsin complexed form of prostate specific antigen

Mk, Brawer; Ferreri, LF; Bankson, DD

doi:10.1038/sj.pcan.4500419

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although ACT biological function is not yet fully understood, it has been suggested that local synthesis of ACT, may be implicated in the regulation of the tumorigenic potential of breast cancer cells, suggesting a role of ACT in breast cancer progression [ 33 ]. Although there is no data about the biological function of ACT in prostate cancer, it has been described that ACT stabilizes PSA plasma levels and the complex ACT-PSA is higher than PSA alone in serum from prostate cancer [ 34 ]. Additional functional studies are needed to determine the exact role of AAT and ACT in prostate and breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: A Role Regulating Tumor Growth

Ashour

Angulo

González-Corpas

et al. 2020

IJMS

View full text Add to dashboard Cite

Prostate and breast cancer constitute the most common cancers among men and women worldwide. The aging population is one of the main risk factors for prostate and breast cancer development and accumulating studies link aging with epigenetic changes. Growth factor independence-1 (Gfi1) is a transcriptional repressor with an important role in human malignancies, including leukemia, colorectal carcinoma, and lung cancer, but its role in prostate and breast cancer is unknown. We have found that Gfi1 epigenetic silencing is a common event in prostate and breast cancer. Gfi1 re-expression in prostate and breast cancer cell lines displaying Gfi1 epigenetic silencing decreases cell proliferation, reduced colony formation density, and tumor growth in nude mice xenografts. In addition, we found that Gfi1 repress alpha 1-anti-trypsin (AAT) and alpha 1-anti-chymotrypsin (ACT) expression, two genes with important functions in cancer development, suggesting that Gfi1 silencing promotes tumor growth by increasing AAT and ACT expression in our system. Finally, Gfi1 epigenetic silencing could be a promising biomarker for prostate cancer progression because it is associated with shorter disease-free survival. In conclusion, our findings strongly indicate that Gfi1 epigenetic silencing in prostate and breast cancer could be a crucial step in the development of these two-well characterized endocrine related tumors.

show abstract

Section: Discussionmentioning

confidence: 99%